Despite big boasts about the novelty of its 5-hydroxytryptamine6 (5-HT6) pathway approach to treat Alzheimer's disease (AD), Axovant Sciences Ltd. found its phase III effort just as wanting as those of every other biopharma that's sought in recent years to tame the deadly neurodegenerative disease.